Suvretta Capital Management, LLC Apellis Pharmaceuticals, Inc. Transaction History
Suvretta Capital Management, LLC
- $2.54 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding APLS
# of Institutions
302Shares Held
112MCall Options Held
3.85MPut Options Held
1.09M-
Wellington Management Group LLP Boston, MA15.6MShares$452 Million0.08% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$345 Million14.88% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.1MShares$322 Million4.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.82MShares$285 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.8MShares$168 Million0.01% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $3.19B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...